Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Μαγδαληνή Μήγκου, Παθολόγος-Ογκολόγος, Θεραπευτική Κλινική, ΓΝΑ «Αλεξάνδρα», Επιβλέπουσα
Μαρία Γαβριατοπούλου, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Δέσποινα Φωτίου, Ιατρός, Θεραπευτική Κλινική, ΓΝΑ «Αλεξάνδρα»
Original Title:
Η κλινική ανάπτυξη της Τεκλισταμάμπης (Teclistamab) στις πλασματοκυτταρικές δυσκρασίες
Translated title:
The clinical development of Teclistamab in plasma cell dyscrasias
Summary:
Multiple Myeloma is a hematologic malignancy that belongs to Plasma Cell dyscrasias. The disease has different stages, while its clinical presentation is characterised by great heterogenicity. Progress has been observed in the last years in the fields of both the diagnosis and the management of the disease. In this context, bispecific antibodies have gained important and active role in the management of Multiple Myeloma. Teclistamab is the first bispecific antibody that was approved for use in patients with Multiple Myeloma. It has two binding sites, one for the CD3 of T cells and one for the BCMA of myeloma cells. Teclistamab has been tried in phases 1, 2, 3 and 4 of clinical trials, either as monotherapy or in combination with other drugs. The first outcomes of these trials are encouraging in their majority, showing that the use of Teclistamab has a positive effect on indexes like overall survival and progression free survival. Moreover, the side effects of Teclistamab are usually well tolerated and are detected early. Data from more trials and studies are needed in order to shed light to some questions arising and to help establish Teclistamab as a cornerstone in the therapeutical management of Multiple Myeloma. The aim of this thesis is to present the latest data in regard to the clinical development of Teclistamab in Plasma Cell Dyscrasias. Thorough review of the literature in databases, scientific magazines and online academic libraries has been made. The results of clinical trials as well as data from various papers and studies concerning Teclistamab are being presented and analysed.
Main subject category:
Health Sciences
Keywords:
Multiple myeloma, Bispecific antibody, Teclistamab
File:
File access is restricted only to the intranet of UoA.
Kremli_Ioulia_MSc.pdf
2 MB
File access is restricted only to the intranet of UoA.
